Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 Vaccine Revaccination in Lung and Kidney Transplant Recipients
NCT07092865Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
A Phase 2 trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Aug 2025; status: active, not recruiting.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07092865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092865.